|
|
双相抑郁的治疗进展
|
Abstract:
双相抑郁是一种复发性疾病，对患者及社会造成严重的负担。目前美国食品药品监督管理局共批准了五种治疗双相抑郁的方案。其中四种是应用第二代抗精神病药物，一种是应用第二代抗精神病药物联合抗抑郁药物。本文回顾了上述五种方案及临床常被使用的药物及非药物治疗方案选择，期望对进一步治疗双相抑郁提供参考。
Bipolar depression is a recurrent disease that causes serious burden to patients and society. Currently, the US Food and Drug Administration has approved five treatment plans for bipolar depression. Four of them are using second-generation antipsychotic drugs, and one is using second-generation antipsychotic drugs in combination with antidepressants. This article reviews the above five regimens and the commonly used drug and non drug treatment options in clinical practice, with the hope of providing reference for further treatment of bipolar depression.
| [1] | Kupka, R.W., Altshuler, L.L., Nolen, W.A., Suppes, T., Luckenbaugh, D.A., Leverich, G.S., et al. (2007) Three Times More Days Depressed than Manic or Hypomanic in Both Bipolar I and Bipolar II Disorder. Bipolar Disorders, 9, 531-535. https://doi.org/10.1111/j.1399-5618.2007.00467.x |
| [2] | Silva, M.T., Zimmermann, I.R., Galvao, T.F. and Pereira, M.G. (2013) Olanzapine plus Fluoxetine for Bipolar Disorder: A Systematic Review and Meta-Analysis. Journal of Affective Disorders, 146, 310-318. https://doi.org/10.1016/j.jad.2012.11.001 |
| [3] | Shen, Y.-C. (2018) Treatment of Acute Bipolar Depression. Tzu Chi Medical Journal, 30, 141-147. https://doi.org/10.4103/tcmj.tcmj_71_18 |
| [4] | Suttajit, S., Srisurapanont, M., Maneeton, N. and Maneeton, B. (2014) Quetiapine for Acute Bipolar Depression: A Systematic Review and Meta-Analysis. Drug Design, Development and Therapy, 8, 827-838. https://doi.org/10.2147/dddt.s63779 |
| [5] | Anderson, S.L. and Vande Griend, J.P. (2014) Quetiapine for Insomnia: A Review of the Literature. American Journal of Health-System Pharmacy, 71, 394-402. https://doi.org/10.2146/ajhp130221 |
| [6] | Loebel, A., Xu, J., Hsu, J., Cucchiaro, J. and Pikalov, A. (2015) The Development of Lurasidone for Bipolar Depression. Annals of the New York Academy of Sciences, 1358, 95-104. https://doi.org/10.1111/nyas.12965 |
| [7] | Fountoulakis, K.N., Gazouli, M., Kelsoe, J. and Akiskal, H. (2015) The Pharmacodynamic Properties of Lurasidone and Their Role in Its Antidepressant Efficacy in Bipolar Disorder. European Neuropsychopharmacology, 25, 335-342. https://doi.org/10.1016/j.euroneuro.2014.11.010 |
| [8] | Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., et al. (2014) Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry, 171, 160-168. https://doi.org/10.1176/appi.ajp.2013.13070984 |
| [9] | Tocco, M., Newcomer, J.W., Mao, Y., Pikalov, A. and Loebel, A. (2020) Lurasidone and Risk for Metabolic Syndrome: Results from Short-and Long-Term Clinical Studies in Patients with Schizophrenia. CNS Spectrums, 26, 614-624. https://doi.org/10.1017/s1092852920001698 |
| [10] | Leggio, G.M., Salomone, S., Bucolo, C., et al. (2013) Dopamine D3 Receptor as a New Pharmacological Target for the Treatment of Depression. European Journal of Pharmacology, 719, 25-33. https://doi.org/10.1016/j.ejphar.2013.07.022 |
| [11] | Pinto, J.V., Saraf, G., Vigo, D., et al. (2020) Cariprazine in the Treatment of Bipolar Disorder: A Systematic Review and Meta-Analysis. Bipolar Disorders, 22, 360-371. https://doi.org/10.1111/bdi.12850 |
| [12] | Antrim, A. (2012) FDA Approves Lumateperone for the Treatment of Bipolar Depression. https://www.pharmacytimes.com/view/fda-approves-lumateperone-for-the-treatment-of-bipolar-depression |
| [13] | Calabrese, J.R., Durgam, S., Satlin, A., Vanover, K.E., Davis, R.E., Chen, R., et al. (2021) Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. American Journal of Psychiatry, 178, 1098-1106. https://doi.org/10.1176/appi.ajp.2021.20091339 |
| [14] | D’Souza, I., Durgam, S., Satlin, A., Davis, R.E., Kozauer, S.G., Chen, R., et al. (2021) Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results from a Randomized Clinical Trial. CNS Spectrums, 26, 150-150. https://doi.org/10.1017/s1092852920002370 |
| [15] | Malhi, G.S., Tanious, M., Das, P., Coulston, C.M. and Berk, M. (2013) Potential Mechanisms of Action of Lithium in Bipolar Disorder. CNS Drugs, 27, 135-153. https://doi.org/10.1007/s40263-013-0039-0 |
| [16] | Fountoulakis, K.N., Grunze, H., Panagiotidis, P., et al. (2008) Treatment of Bipolar Depression: An Update. Journal of Affective Disorders, 109, 21-34. https://doi.org/10.1016/j.jad.2007.10.016 |
| [17] | Gershon, S., Chengappa, K.R. and Malhi, G.S. (2009) Lithium Specificity in Bipolar Illness: A Classic Agent for the Classic Disorder. Bipolar Disorders, 11, 34-44. https://doi.org/10.1111/j.1399-5618.2009.00709.x |
| [18] | Sarai, S.K., Mekala, H.M. and Lippmann, S. (2018) Lithium Suicide Prevention: A Brief Review and Reminder. Innovations in Clinical Neuroscience, 15, 30-32. |
| [19] | 唐瑛, 吕东升, 柳亭. 拉莫三嗪在双相情感障碍患者中的研究进展[J]. 内蒙古医学杂志, 2023, 55(3): 321-324, 328. https://doi.org/10.16096/J.cnki.nmgyxzz.2023.55.03.017 |
| [20] | Geddes, J.R., Calabrese, J.R. and Goodwin, G.M. (2009) Lamotrigine for Treatment of Bipolar Depression: Independent Meta-Analysis and Meta-Regression of Individual Patient Data from Five Randomised Trials. British Journal of Psychiatry, 194, 4-9. https://doi.org/10.1192/bjp.bp.107.048504 |
| [21] | Van der Loos, M.L., Mulder, P.G.H., Hartong, E.G., Blom, M.B., Vergouwen, A.C., de Keyzer, H.J., et al. (2009) Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression: A Multicenter, Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Psychiatry, 70, 223-231. https://doi.org/10.4088/JCP.08m04152 |
| [22] | Bloom, R. and Amber, K.T. (2017) Identifying the Incidence of Rash, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Patients Taking Lamotrigine: A Systematic Review of 122 Randomized Controlled Trials. Anais Brasileiros de Dermatologia, 92, 139-141. https://doi.org/10.1590/abd1806-4841.20175070 |
| [23] | Sachs, G.S., Nierenberg, A.A., Calabrese, J.R., Marangell, L.B., Wisniewski, S.R., Gyulai, L., et al. (2007) Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. New England Journal of Medicine, 356, 1711-1722. https://doi.org/10.1056/nejmoa064135 |
| [24] | Gijsman, H.J., Geddes, J.R., Rendell, J.M., Nolen, W.A. and Goodwin, G.M. (2004) Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials. American Journal of Psychiatry, 161, 1537-1547. https://doi.org/10.1176/appi.ajp.161.9.1537 |
| [25] | Vieta, E., Martinez-Aran, A., Goikolea, J.M., Torrent, C., Colom, F., Benabarre, A., et al. (2002) A Randomized Trial Comparing Paroxetine and Venlafaxine in the Treatment of Bipolar Depressed Patients Taking Mood Stabilizers. The Journal of Clinical Psychiatry, 63, 508-512. https://doi.org/10.4088/jcp.v63n0607 |
| [26] | Ramic, E., Prasko, S., Gavran, L. and Spahic, E. (2020) Assessment of the Antidepressant Side Effects Occurrence in Patients Treated in Primary Care. Materia Socio Medica, 32, 131-134. https://doi.org/10.5455/msm.2020.32.131-134 |
| [27] | Fava, M., Rush, A.J., Thase, M.E., Clayton, A., Stahl, S.M., Pradko, J.F., et al. (2005) 15 Years of Clinical Experience with Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL. Primary Care Companion for CNS Disorders, 7, 106-113. https://doi.org/10.4088/pcc.v07n0305 |
| [28] | Popiolek, K., Bejerot, S., Brus, O., Hammar, A., et al. (2019) Electroconvulsive Therapy in Bipolar Depression-Effectiveness and Prognostic Factors. Acta Psychiatrica Scandinavica, 140, 196-204. https://doi.org/10.1111/acps.13075 |
| [29] | Nguyen, T.D., Hieronymus, F., Lorentzen, R., McGirr, A. and ？stergaard, S.D. (2021) The Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMs) for Bipolar Depression: A Systematic Review and Meta-Analysis. Journal of Affective Disorders, 279, 250-255. https://doi.org/10.1016/j.jad.2020.10.013 |
